We've been using Merck's technology for quite some time now... Since 2005 Hmmmm... Peregrine to Use Merck KGaA's Protein Expression Technology
Peregrine Pharmaceuticals, a biopharmaceutical company with a broad portfolio of products under development, today announced that the company has entered into an agreement with Merck KGaA of Darmstadt, Germany, that will give Peregrine access to Merck's technology and expertise in protein expression. The goal of the collaboration is to use protein expression technologies developed by Merck's affiliate EMD Lexigen Research Center to advance the development of Peregrine's VEA technology platform. In addition, Peregrine will gain access to Merck's proprietary protein expression system to develop and enhance other antibodies and antibody-based fusion proteins under its Vascular Targeting Agent, Anti-Phospholipid and Anti-Angiogenesis programs.